Precipio — Q3-2026 Earnings Summary

Financial Performance:

• Revenue reached $7.3 million, an 8% increase year-over-year from $6.8 million in Q3-2025 and up from $7.0 million in Q2-2026.
• Product revenue was $1.0 million, representing a 40% year-over-year increase from $0.7 million in Q3-2025 and up from $0.9 million in Q2-2026.
• Pathology revenue was $6.3 million, a 5% year-over-year increase from $6.0 million in Q3-2025 and up from $6.1 million in Q2-2026.
• Adjusted EBITDA was $0.4 million, compared to $0.5 million in Q3-2025 and $0.4 million in Q2-2026.
• Cash flow from operations was $0.6 million.
• Total cash increased by $0.5 million, resulting in an end-of-quarter cash balance exceeding $3.5 million, compared to $2.3 million in Q3-2025.
• GAAP Net Income was $0.0 million, compared to a loss of $0.1 million in Q3-2025.
• EBITDA was $0.3 million, matching the $0.3 million reported in Q3-2025.
• Stock-based compensation expense was $0.1 million, down from $0.2 million in Q3-2025.

Guidance and Future Outlook:

• Management stated the company is well-positioned to accelerate the commercialization of its existing product portfolio.
• The company aims to pursue significant longer-term growth opportunities.
• The pathology business serves as a clinical development and validation platform for proprietary diagnostic products.

Business Segments and Product Lines:

• The company operates two primary revenue streams: product revenue and pathology revenue.
• The pathology business provides a strong operational and financial foundation for growth.
• Precipio develops innovative technologies in its laboratory, including design, testing, validation, and clinical use, which are then commercialized as proprietary products.

Management Commentary and Tone:

• CEO Ilan Danieli described the quarter as one where the company continued to strengthen its financial position, delivering record revenue while maintaining positive Adjusted EBITDA and generating cash from operations.
• Management expressed confidence that the company's cash position and operational foundation support accelerated commercialization.

Other Key Points:

• A shareholder call was scheduled for November 10, 2026, at 5 PM ET, featuring management remarks and a moderated Q&A session.
• The press release references a Form 10-Q filed on the same day for additional results.
• The company is a healthcare biotechnology firm focused on cancer diagnostics, aiming to address cancer misdiagnoses through higher accuracy and improved laboratory workflow.
• Forward-looking statements include risks related to future volumes, sales, growth, costs, margins, and earnings, with actual results potentially differing materially from projections.
• The company communicates with investors via its website, X (formerly Twitter), LinkedIn, and Facebook.